A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
Clinical trial NCT03568071 · TERMINATED
Trial details
- NCT number
- NCT03568071
- Sponsor
- Lakefront Biotherapeutics NV
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-26
- Primary completion
- 2020-03-03
- Enrollment
- 207
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.